Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 4/20 | 1.00 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.98 |
| ▸ | TYMP | P19971 | 3/20 | 0.50 |
| ▸ | HPRT1 | P00492 | 7/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | NT5E | P21589 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cidofovir Anhydrous SCHEMBL3948 | 1.00 | FGFR1 (1.00) | FGFR1SLC22A6TYMPHPRT1CYP3A4 | |
| Cidofovir Anhydrous SCHEMBL14682730 | 1.00 | FGFR1 (1.00) | FGFR1SLC22A6TYMPHPRT1CYP3A4 | |
| Cidofovir Anhydrous SCHEMBL151807 | 1.00 | FGFR1 (1.00) | FGFR1SLC22A6TYMPHPRT1CYP3A4 | |
| Cidofovir Anhydrous SCHEMBL2946566 | 0.99 | SLC22A6 (1.00) | FGFR1SLC22A6TYMPHPRT1CYP3A4 | |
| Cidofovir Anhydrous SCHEMBL20770422 | 0.99 | FGFR1 (0.98) | FGFR1SLC22A6TYMPHPRT1CYP3A4 | |
| Cidofovir Anhydrous SCHEMBL12988503 | 0.99 | SLC22A6 (1.00) | FGFR1SLC22A6TYMPHPRT1CYP3A4 | |
| Cidofovir Anhydrous SCHEMBL934593 | 0.99 | FGFR1 (0.98) | FGFR1SLC22A6TYMPHPRT1CYP3A4 | |
| Cidofovir Anhydrous SCHEMBL2946561 | 0.99 | SLC22A6 (1.00) | FGFR1SLC22A6TYMPHPRT1CYP3A4 | |
| Cidofovir Anhydrous SCHEMBL28935227 | 0.99 | FGFR1 (0.98) | FGFR1SLC22A6TYMPHPRT1CYP3A4 | |
| Cidofovir Anhydrous SCHEMBL27629017 | 0.99 | FGFR1 (0.98) | FGFR1SLC22A6TYMPHPRT1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112592953-A | High-throughput screening method for human adenovirus proliferation inhibition drug and application thereof | 中国农业科学院上海兽医研究所(中国动物卫生与流行病学中心上海分中心) | 2021-04-02 | — | — | CN | claimed |
| CN-112592953-A | High-throughput screening method for human adenovirus proliferation inhibition drug and application thereof | 中国农业科学院上海兽医研究所(中国动物卫生与流行病学中心上海分中心) | 2021-04-02 | — | — | CN | disclosed |
| EP-3675838-A1 | LYMPHATIC SYSTEM-DIRECTING LIPID PRODRUGS | Puretecch LYT, Inc. (US) | 2020-07-08 | — | — | EP | disclosed |
| WO-2019046491-A1 | LYMPHATIC SYSTEM-DIRECTING LIPID PRODRUGS | ARIYA THERAPEUTICS, INC. (US) | 2019-03-07 | — | — | WO | disclosed |
| WO-2018156879-A1 | TREATMENT OF ADENOVIRUS WITH BRINCIDOFOVIR | CHIMERIX, INC. (US) | 2018-08-30 | — | — | WO | disclosed |
| US-20160303147-A1 | METHODS OF REDUCING NEPHROTOXICITY IN SUBJECTS ADMINISTERED WITH NUCLEOSIDE PHOSPHONATES | CHIMERIX, INC. | 2016-10-20 | — | — | US | disclosed |
| EP-2155257-B1 | METHODS OF REDUCING NEPHROTOXICITY IN SUBJECTS ADMINISTERED WITH NUCLEOSIDE | CHIMERIX INC (US) | 2016-10-05 | — | — | EP | disclosed |
| US-20120010170-A1 | \"Methods of Reducing Nephrotoxicity in Subjects Administered Nucleoside Phosphonates\ | EMERGENT BIODEFENSE OPERATIONS LANSING LLC | 2012-01-12 | — | — | US | disclosed |
| EP-2155257-A1 | METHODS OF REDUCING NEPHROTOXICITY IN SUBJECTS ADMINISTERED WITH NUCLEOSIDE | Chimerix, Inc. (US) | 2010-02-24 | — | — | EP | disclosed |
| EP-2125024-A2 | TARGETED INTRACELLULAR DELIVERY OF ANTIVIRAL AGENTS | TO-BBB Holding B.V. (NL) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008133966-A1 | METHODS OF REDUCING NEPHROTOXICITY IN SUBJECTS ADMINISTERED WITH NUCLEOSIDE | CHIMERIX, INC. (US) | 2008-11-06 | — | — | WO | disclosed |
| WO-2008118013-A2 | TARGETED INTRACELLULAR DELIVERY OF ANTIVIRAL AGENTS | TO-BBB HOLDING B.V. (NL) | 2008-10-02 | — | — | WO | disclosed |
| US-5869468-A | Treatment of conditions of abnormally increased intraocular pressure by administration of phosphonylmethoxyalkyl nucleoside analogs and related nucleoside analogs | FREEMAN WILLIAM R (US) | 1999-02-09 | — | — | US | disclosed |
| US-5756486-A | CYCLIZED NUCLEOTIDE; VIRICIDE | GILEAD SCIENCES, INC. (US) | 1998-05-26 | — | — | US | disclosed |
| US-5591851-A | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 1997-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160303147-A1 | METHODS OF REDUCING NEPHROTOXICITY IN SUBJECTS ADMINISTERED WITH NUCLEOSIDE PHOSPHONATES | SLC29A1, SLC28A1, PHOSPHO1 | FGFR1 3173/4885SLC22A6 166/4885TYMP 46/4885 |
| US-20120010170-A1 | \"Methods of Reducing Nephrotoxicity in Subjects Administered Nucleoside Phosphonates\ | CSGALNACT1, SLC28A1, SLC10A1 | FGFR1 3225/4885SLC22A6 401/4885TYMP 140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.